Actively Recruiting
Multi-center Prospective Study of EUS-guided Radiofrequency Ablation for Treating Solid Tumors in the Abdomen
Led by Chinese University of Hong Kong · Updated on 2026-03-20
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate EUS-guided radiofrequency ablation RFA as a treatment for solid abdominal neoplasms, including tumors in the liver, stomach, kidney, and adrenal glands. The study is a multi-center prospective trial involving patients with tumors less than 5 cm in size who are not suitable for surgery. The goal is to assess the safety, feasibility, and effectiveness of this minimally invasive approach for these solid tumors. The treatment involves using a 19-gauge RFA electrode guided by endoscopic ultrasound EUS to deliver high-frequency alternating current that heats and destroys tumor tissue through coagulative necrosis. The procedure includes locating the tumor with a linear array echoendoscope, inserting the RFA needle into the lesion, and applying heat based on tumor size. This study is conducted across several high-volume international centers using specialized devices, including the VIVA RF generator. Participants will undergo assessments before and after the procedure, including imaging to evaluate tumor response and monitoring for adverse events within 30 days. Researchers will measure technical success, procedural time, hospital stay, need for re-interventions, and survival rates at 1 and 3 years. Safety is a primary focus, with attention to severe adverse events shortly after treatment. The total follow-up period extends up to 3 years to understand long-term outcomes.
CONDITIONS
Brief Title
EUS-guided RFA for Solid Abdominal Neoplasms
Research Team
A
Anthony YB Teoh, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here